URILEF 100MG TABLET

Description

URILEF 100MG TABLET

URILEF 100MG TABLET contains Phenazopyridine HCl which is an azo dye that exerts an analgesic effect. The chemical name of URILEF 100MG TABLET is 2, 6-pyridinediamine, 3-(phenylazo)-, monohydrochloride. URILEF 100MG TABLET molecular formula is C11H11N5 • HCl. URILEF 100MG TABLET produces an orange to red colour in the urine and feces and may cause staining.URILEF 100MG TABLET may cause discoloration of body fluids and staining of contact lenses has been reported. A yellowish colour of the skin or sclerae may indicate accumulation of URILEF 100MG TABLET resulting from impaired renal function and necessitates discontinuance of the drug. It should be noted that a decline in renal function is common in elderly patients. • Cautious use in patients with G-6-PD deficiency is advised since these patients are susceptible to oxidative hemolysis and may have greater potential to develop hemolytic anemia.

Uses

Urilef (Phenazopyridine HCl) is indicated for the symptomatic relief of pain and irritability in conditions such as cystitis, prostatitis and urethritis; burning, urgency, frequency and other discomforts resulting from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures or the passage of sounds or catheters. Phenazopyridine HCl is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine HCl should not exceed 2 days..

 Side effect :

Nausea, vomiting, diarrhea, headache, aseptic meningitis, rash, pruritus, discoloration, jaundice, renal toxicity usually associated with overdose, renal calculi, methemoglobinemia, hemolytic anemia, acute renal failure, potential hemolytic agent in G-6-PD deficiency

 When not use :

Phenazopyridine HCl is contraindicated; • In patients with known hypersensitivity to Phenazopyridine HCl or to any excipient of the product. • In patients with renal insufficiency (including glomerulonephritis, uremia, pyelonephritis during pregnancy or impaired renal function). • In patients with severe liver disease.